CENTOGENE NV (CNTG) Stock Price & Overview

NASDAQ:CNTG • NL0014040206

Current stock price

0.325 USD
-0.02 (-6.23%)
At close:
0.351 USD
+0.03 (+8%)
After Hours:

The current stock price of CNTG is 0.325 USD. Today CNTG is down by -6.23%. In the past month the price decreased by -33.52%. In the past year, price decreased by -68.45%.

CNTG Key Statistics

52-Week Range0.2511 - 1.53
Current CNTG stock price positioned within its 52-week range.
1-Month Range0.2511 - 0.5501
Current CNTG stock price positioned within its 1-month range.
Market Cap
8.97M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.39
Dividend Yield
N/A

CNTG Stock Performance

Today
-6.23%
1 Week
-0.31%
1 Month
-33.52%
3 Months
-16.67%
Longer-term
6 Months -68.45%
1 Year -68.45%
2 Years -77.74%
3 Years -96.89%
5 Years N/A
10 Years N/A

CNTG Stock Chart

CENTOGENE NV / CNTG Daily stock chart

CNTG Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to CNTG. When comparing the yearly performance of all stocks, CNTG is a bad performer in the overall market: 92.29% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CNTG Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CNTG. Both the profitability and financial health of CNTG have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CNTG Earnings

Next Earnings DateSep 4, 2024
Last Earnings DateJun 17, 2024
PeriodQ4 / 2023
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise 280.67%

CNTG Forecast & Estimates

7 analysts have analysed CNTG and the average price target is 1.53 USD. This implies a price increase of 370.77% is expected in the next year compared to the current price of 0.325.

For the next year, analysts expect an EPS growth of 39.38% and a revenue growth 22.37% for CNTG


Analysts
Analysts82.86
Price Target1.53 (370.77%)
EPS Next Y39.38%
Revenue Next Year22.37%

CNTG Groups

Sector & Classification

Index Membership

CNTG Financial Highlights

Over the last trailing twelve months CNTG reported a non-GAAP Earnings per Share(EPS) of -1.39. The EPS decreased by -6.92% compared to the year before.


Income Statements
Revenue(TTM)48.54M
Net Income(TTM)-35.53M
Industry RankSector Rank
PM (TTM) N/A
ROA -46.05%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-6.92%
Sales Q2Q%254.74%
EPS 1Y (TTM)-6.92%
Revenue 1Y (TTM)2.25%

CNTG Ownership

Ownership
Inst Owners0.09%
Shares27.60M
Float18.60M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

CNTG Competitors/Peers

The largest stocks on the US markets in the "Health Care Services" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
CVS CVS HEALTH CORP10.5496.853B
CI THE CIGNA GROUP8.6270.413B
BTSGU BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/2792.5624.843B
DGX QUEST DIAGNOSTICS INC18.5721.941B
LH LABCORP HOLDINGS INC14.5921.737B
GH GUARDANT HEALTH INC N/A11.214B
DVA DAVITA INC10.5610.068B
BTSG BRIGHTSPRING HEALTH SERVICES28.277.415B
HIMS HIMS & HERS HEALTH INC44.395.646B
CHE CHEMED CORP16.425.534B
RDNT RADNET INC78.634.805B
OPCH OPTION CARE HEALTH INC15.544.582B
HNGE HINGE HEALTH INC-A22.743.542B

About CNTG

Company Profile

CNTG logo image Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.

Company Info

IPO: 2019-11-07

CENTOGENE NV

Am Strande 7

Rostock MECKLENBURG-VORPOMMERN 18055 DE

CEO: Andrin Oswald

Employees: 493

CNTG Company Website

Phone: 4938180113400

CENTOGENE NV / CNTG FAQ

Can you describe the business of CENTOGENE NV?

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.


What is the stock price of CENTOGENE NV today?

The current stock price of CNTG is 0.325 USD. The price decreased by -6.23% in the last trading session.


Does CNTG stock pay dividends?

CNTG does not pay a dividend.


What is the ChartMill technical and fundamental rating of CNTG stock?

CNTG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Which stock exchange lists CNTG stock?

CNTG stock is listed on the Nasdaq exchange.


What do analysts say about CENTOGENE NV (CNTG) stock?

7 analysts have analysed CNTG and the average price target is 1.53 USD. This implies a price increase of 370.77% is expected in the next year compared to the current price of 0.325.